Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : INCB086550
CAS No.: 2230911-59-6
Catalog No.: PC-72848Not For Human Use, Lab Use Only.
INCB086550 (INCB 086550) is a potent, selective small-molecule inhibitor of PD-L1, inhibits PD-L1/PD-1 interaction with IC50 of 3.1, 4.9 and 1.9 nM for human, cynomolgus and rat PD-L1 in HTRF-based assays.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $328 | In stock | |
| 10 mg | $528 | In stock | |
| 25 mg | $898 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
INCB086550 (INCB 86550) is a potent, selective small-molecule inhibitor of PD-L1, inhibits PD-L1/PD-1 interaction with IC50 of 3.1, 4.9 and 1.9 nM for human, cynomolgus and rat PD-L1 in HTRF-based assays.
INCB086550 inhibited binding of phycoerythrin (PE)-labeled PD-1 (PD-1/PE) to cell surface PD-L1 with IC50 of 13 nM.
INCB086550 blocked binding of the clinical anti–PD-L1 monoclonal antibodies (mAbs), atezolizumab and durvalumab, to PD-L1, potently and selectively binds to PD-L1 at a site that overlaps with the clinical anti-PD-L1 mAbs.
INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
INCB086550 effectively restored NFAT pathway activation and abolished SHP recruitment to PD-1, thereby demonstrating functional 346 inhibition of the PD-L1/PD-1 signaling pathway.
INCB086550 dose-dependently reduced unoccupied cell surface PD-L1 on the tumor cell surface in vivo, effectively inhibited tumor growth as a single agent in multiple humanized tumor models and was well tolerated.
INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade in vivo.
Oral administration of INCB086550 provides dose-related pharmacodynamic immune activation similar to that reported for PD-L1 or PD-1 therapeutic antibodies.
| M.Wt | 693.808 | |
| Formula | C41H39N7O4 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
(S)-1-((7-cyano-2-(3'-((3-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid |
|
1. Holly K Koblish, et al. Cancer Discov. 2022 Mar 7;candisc.1156.2021.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
